2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
August 9th 2017
Joel Neal, MD, an assistant professor of medicine and oncology at Stanford Medicine, discusses whether, if approved by the FDA, alectinib (Alecensa) will become the frontline standard of care for patients with ALK-positive non–small cell lung cancer (NSCLC).